Pia D. Vogel

Pia D. Vogel

Auto-generated profile, based on publicly available information

Pia D. Vogel

Department of Biological Sciences, Southern Methodist University, Dallas, Texas, United States of America

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ANAmila K. Nanayakkara
Amila K. Nanayakkara
CFCourtney A. Follit
Courtney A. Follit
GCGang Chen
Gang Chen
NWNoelle S. Williams
Noelle S. Williams
PVPia D. Vogel
Pia D. Vogel
JWJohn G. Wise
John G. Wise
Overexpression of ATP-binding cassette (ABC) transporters is often linked to multidrug resistance (MDR) in cancer chemotherapies. P-glycoprotein (P-gp) is one of the best studied drug transporters associated with MDR. There are currently no approved drugs available for clinical use in cancer chemotherapies to reverse MDR by inhibiting P-glycoprotein. Using computational studies, we previously identified several compounds that inhibit P-gp by targeting its nucleotide binding domain and avoiding its drug binding domains. Several of these compounds showed successful MDR reversal when tested on a drug resistant prostate cancer cell line. Using conventional two-dimensional cell culture of MDR ovarian and prostate cancer cells and three dimensional prostate cancer microtumor spheroids, we demonstrated here that co-administration with chemotherapeutics significantly decreased cell viability and survival as well as cell motility. The P-gp inhibitors were not observed to be toxic on their own. The inhibitors increased cellular retention of chemotherapeutics and reporter compounds known to be transport substrates of P-gp. We also showed that these compounds are not transport substrates of P-gp and that two of the three inhibit P-gp, but not the closely related ABC transporter, ABCG2/BCRP. The results presented suggest that these P-gp inhibitors may be promising leads for future drug development.

1 July 1997 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
TSThomas Scheibel
Thomas Scheibel
SNSonja Neuhofen
Sonja Neuhofen
TWTina Weikl
Tina Weikl
CMChristian Mayr
Christian Mayr
JRJochen Reinstein
Jochen Reinstein
JBJohannes Buchner
Johannes Buchner
Hsp90 is one of the most abundant proteins in the cytosol of eukaryotic cells. Under physiological conditions Hsp90 has been shown to play a major role in several specific signaling pathways, including maturation of various kinases and maintenance of steroid receptors in an activable state. It is well established that the level of Hsp90 increases severalfold under stress conditions, and it has been shown that the chaperone function of Hsp90 is ATP-independent. Although yeast Hsp90 does not bind ATP, as determined by a number of methods monitoring tight binding, ATP-dependent functions of Hsp90 in the presence of co-factors and elevated temperatures are still under discussion. Here, we have reinvestigated ATP-binding properties and ATPase activity of human Hsp90 under various conditions. We show that human Hsp90 does not bind ATP tightly and does not exhibit detectable ATPase activity. However, using electron spin resonance spectroscopy, weak binding of spin-labeled ATP analogues with half-maximal binding at 400 μm ATP was detected. The functional significance of this weak interaction remains enigmatic.

10 July 2015 in Biochemistry
Verified
Journal Article
Closed access
JMJames W. McCormick
James W. McCormick
PVPia D. Vogel
Pia D. Vogel
JWJohn G. Wise
John G. Wise

1 October 2005 in Biochemistry
Verified
Journal Article
Closed access
SDSabine Delannoy
Sabine Delannoy
IUIna L. Urbatsch
Ina L. Urbatsch
GTGregory Tombline
Gregory Tombline
ASAlan E. Senior
Alan E. Senior
PVPia D. Vogel
Pia D. Vogel

1 February 2012 in Physiology & Behavior
Verified
Journal Article
Closed access
ATAna F. Trueba
Ana F. Trueba
DMDario Mizrachi
Dario Mizrachi
RARichard J. Auchus
Richard J. Auchus
PVPia D. Vogel
Pia D. Vogel
TRThomas Ritz
Thomas Ritz

1 December 2014 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
FBFrances K. Brewer
Frances K. Brewer
CFCourtney A. Follit
Courtney A. Follit
PVPia D. Vogel
Pia D. Vogel
JWJohn G. Wise
John G. Wise
Multidrug resistances and the failure of chemotherapies are often caused by the expression or overexpression of ATP-binding cassette transporter proteins such as the multidrug resistance protein, P-glycoprotein (P-gp). P-gp is expressed in the plasma membrane of many cell types and protects cells from accumulation of toxins. P-gp uses ATP hydrolysis to catalyze the transport of a broad range of mostly hydrophobic compounds across the plasma membrane and out of the cell. During cancer chemotherapy, the administration of therapeutics often selects for cells which overexpress P-gp, thereby creating populations of cancer cells resistant to a variety of chemically unrelated chemotherapeutics. The present study describes extremely high-throughput, massively parallel in silico ligand docking studies aimed at identifying reversible inhibitors of ATP hydrolysis that target the nucleotide-binding domains of P-gp. We used a structural model of human P-gp that we obtained from molecular dynamics experiments as the protein target for ligand docking. We employed a novel approach of subtractive docking experiments that identified ligands that bound predominantly to the nucleotide-binding domains but not the drug-binding domains of P-gp. Four compounds were found that inhibit ATP hydrolysis by P-gp. Using electron spin resonance spectroscopy, we showed that at least three of these compounds affected nucleotide binding to the transporter. These studies represent a successful proof of principle demonstrating the potential of targeted approaches for identifying specific inhibitors of P-gp.